Skip to main content

Table 5 Effects of each treatment on TXB2, 6-keto-PGF and the TXB2/6-keto-PGF1a ratio in k-carrageenan-induced rat tail thrombosis model (n = 10)

From: Evaluation on antithrombotic effect of aspirin eugenol ester from the view of platelet aggregation, hemorheology, TXB2/6-keto-PGF and blood biochemistry in rat model

Groups

TXB2

6-keto-PGF

TXB2/6-keto-PGF

Control

498 ± 32##

889 ± 28##

0.56 ± 0.04##

Model

696 ± 39

586 ± 24

1.19 ± 0.08

CMC-Na

703 ± 37

550 ± 22##

1.28 ± 0.08##

Aspirin

658 ± 44*

741 ± 23**

0.89 ± 0.06**

Eugenol

678 ± 58

699 ± 30**

0.97 ± 0.09**

AEE L

605 ± 22**

667 ± 17**

0.91 ± 0.04**

AEE M

612 ± 45**

737 ± 13**

0.83 ± 0.07**

AEE H

644 ± 23**

599 ± 26**

1.08 ± 0.07**

Combination

598 ± 51**

701 ± 31**

0.86 ± 0.10**

  1. Blood samples anticoagulated with EDTA-K2 were centrifuged at 1000 g for 10 min to obtain plasma, which was analyzed using ELISA kits. Data are expressed as mean ± SD. ## P < 0.01 compared with the model group. *P < 0.05, **P < 0.01 compared with the CMC-Na group. AEE L: AEE 18 mg/kg; AEE M: 36 mg/kg; AEE H: AEE 72 mg/kg; Combination: combination of aspirin and eugenol (molar ratio 1:1)